百威亞太(1876.HK)低開2.67% 四季度和全年業績均不及預期
格隆匯2月27日丨今早公佈業績的百威亞太(1876.HK)低開2.67%報港元,盤前成交1279.6萬港元,最新總市值3132億港元。該股自2019年10月9日創出上市新高32.65港元后一路下跌至今,曾於2月25日盤中創出上市新低價23.05港元,4個多月期間最大跌幅一度達29%。最新公佈的財報顯示,公司2019年第四季度收入12億美元,市場預期12.6億美元;2019年第四季度淨利潤4500萬美元,市場預期5286萬美元。2019年收入65.46億美元,市場預期66.38億美元;2019年淨利潤8.98億美元,市場預期9.68億美元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.